Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression

PURPOSE: Outcomes after the treatment for unresectable or advanced-stage hepatocellular carcinoma (HCC) are unsatisfied. We evaluated the therapeutic benefits of a combination therapy strategy for these patients through transarterial chemoembolization (TACE) plus sorafenib. PATIENTS AND METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Xinhua, Fan, Wenzhe, Xue, Miao, Li, Jiaping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142557/
https://www.ncbi.nlm.nih.gov/pubmed/34040442
http://dx.doi.org/10.2147/CMAR.S304591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142557/
https://www.ncbi.nlm.nih.gov/pubmed/34040442
http://dx.doi.org/10.2147/CMAR.S304591

Ejemplares similares